1
|
Hayes TR, Chao CK, Blecha JE, Huynh TL, VanBrocklin HF, Zinn KR, Gerdes JM, Thompson CM. [ 11C]Paraoxon: Radiosynthesis, Biodistribution and In Vivo Positron Emission Tomography Imaging in Rat. J Pharmacol Exp Ther 2024; 388:333-346. [PMID: 37770203 PMCID: PMC10801775 DOI: 10.1124/jpet.123.001832] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Revised: 08/31/2023] [Accepted: 09/05/2023] [Indexed: 10/03/2023] Open
Abstract
Synthesis of the acetylcholinesterase inhibitor paraoxon (POX) as a carbon-11 positron emission tomography tracer ([11C]POX) and profiling in live rats is reported. Naïve rats intravenously injected with [11C]POX showed a rapid decrease in parent tracer to ∼1%, with an increase in radiolabeled serum proteins to 87% and red blood cells (RBCs) to 9%. Protein and RBC leveled over 60 minutes, reflecting covalent modification of proteins by [11C]POX. Ex vivo biodistribution and imaging profiles in naïve rats had the highest radioactivity levels in lung followed by heart and kidney, and brain and liver the lowest. Brain radioactivity levels were low but observed immediately after injection and persisted over the 60-minute experiment. This showed for the first time that even low POX exposures (∼200 ng tracer) can rapidly enter brain. Rats given an LD50 dose of nonradioactive paraoxon at the LD50 20 or 60 minutes prior to [11C]POX tracer revealed that protein pools were blocked. Blood radioactivity at 20 minutes was markedly lower than naïve levels due to rapid protein modification by nonradioactive POX; however, by 60 minutes the blood radioactivity returned to near naïve levels. Live rat tissue imaging-derived radioactivity values were 10%-37% of naïve levels in nonradioactive POX pretreated rats at 20 minutes, but by 60 minutes the area under the curve (AUC) values had recovered to 25%-80% of naïve. The live rat imaging supported blockade by nonradioactive POX pretreatment at 20 minutes and recovery of proteins by 60 minutes. SIGNIFICANCE STATEMENT: Paraoxon (POX) is an organophosphorus (OP) compound and a powerful prototype and substitute for OP chemical warfare agents (CWAs) such as sarin, VX, etc. To study the distribution and penetration of POX into the central nervous system (CNS) and other tissues, a positron emission tomography (PET) tracer analog, carbon-11-labeled paraoxon ([11C]POX), was prepared. Blood and tissue radioactivity levels in live rats demonstrated immediate penetration into the CNS and persistent radioactivity levels in tissues indicative of covalent target modification.
Collapse
Affiliation(s)
- Thomas R Hayes
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (C.-K.C., J.M.G., C.M.T.); Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California (T.R.H., J.E.B., T.L.H., H.F.V.); and Departments of Radiology, Small Animal Clinical Sciences, and Biomedical Engineering and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan (K.R.Z.)
| | - Chih-Kai Chao
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (C.-K.C., J.M.G., C.M.T.); Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California (T.R.H., J.E.B., T.L.H., H.F.V.); and Departments of Radiology, Small Animal Clinical Sciences, and Biomedical Engineering and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan (K.R.Z.)
| | - Joseph E Blecha
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (C.-K.C., J.M.G., C.M.T.); Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California (T.R.H., J.E.B., T.L.H., H.F.V.); and Departments of Radiology, Small Animal Clinical Sciences, and Biomedical Engineering and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan (K.R.Z.)
| | - Tony L Huynh
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (C.-K.C., J.M.G., C.M.T.); Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California (T.R.H., J.E.B., T.L.H., H.F.V.); and Departments of Radiology, Small Animal Clinical Sciences, and Biomedical Engineering and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan (K.R.Z.)
| | - Henry F VanBrocklin
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (C.-K.C., J.M.G., C.M.T.); Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California (T.R.H., J.E.B., T.L.H., H.F.V.); and Departments of Radiology, Small Animal Clinical Sciences, and Biomedical Engineering and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan (K.R.Z.)
| | - Kurt R Zinn
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (C.-K.C., J.M.G., C.M.T.); Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California (T.R.H., J.E.B., T.L.H., H.F.V.); and Departments of Radiology, Small Animal Clinical Sciences, and Biomedical Engineering and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan (K.R.Z.)
| | - John M Gerdes
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (C.-K.C., J.M.G., C.M.T.); Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California (T.R.H., J.E.B., T.L.H., H.F.V.); and Departments of Radiology, Small Animal Clinical Sciences, and Biomedical Engineering and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan (K.R.Z.)
| | - Charles M Thompson
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (C.-K.C., J.M.G., C.M.T.); Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California (T.R.H., J.E.B., T.L.H., H.F.V.); and Departments of Radiology, Small Animal Clinical Sciences, and Biomedical Engineering and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan (K.R.Z.)
| |
Collapse
|
2
|
Midha AD, Zhou Y, Queliconi BB, Barrios AM, Haribowo AG, Chew BTL, Fong COY, Blecha JE, VanBrocklin H, Seo Y, Jain IH. Organ-specific fuel rewiring in acute and chronic hypoxia redistributes glucose and fatty acid metabolism. Cell Metab 2023; 35:504-516.e5. [PMID: 36889284 PMCID: PMC10077660 DOI: 10.1016/j.cmet.2023.02.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Revised: 12/20/2022] [Accepted: 02/08/2023] [Indexed: 03/09/2023]
Abstract
Oxygen deprivation can be detrimental. However, chronic hypoxia is also associated with decreased incidence of metabolic syndrome and cardiovascular disease in high-altitude populations. Previously, hypoxic fuel rewiring has primarily been studied in immortalized cells. Here, we describe how systemic hypoxia rewires fuel metabolism to optimize whole-body adaptation. Acclimatization to hypoxia coincided with dramatically lower blood glucose and adiposity. Using in vivo fuel uptake and flux measurements, we found that organs partitioned fuels differently during hypoxia adaption. Acutely, most organs increased glucose uptake and suppressed aerobic glucose oxidation, consistent with previous in vitro investigations. In contrast, brown adipose tissue and skeletal muscle became "glucose savers," suppressing glucose uptake by 3-5-fold. Interestingly, chronic hypoxia produced distinct patterns: the heart relied increasingly on glucose oxidation, and unexpectedly, the brain, kidney, and liver increased fatty acid uptake and oxidation. Hypoxia-induced metabolic plasticity carries therapeutic implications for chronic metabolic diseases and acute hypoxic injuries.
Collapse
Affiliation(s)
- Ayush D Midha
- Gladstone Institutes, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA; Medical Scientist Training Program, University of California, San Francisco, San Francisco, CA 94143, USA; Tetrad Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA
| | - Yuyin Zhou
- Gladstone Institutes, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA
| | - Bruno B Queliconi
- Gladstone Institutes, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA
| | - Alec M Barrios
- Gladstone Institutes, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA
| | - Augustinus G Haribowo
- Gladstone Institutes, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA
| | - Brandon T L Chew
- Gladstone Institutes, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA; Pharmaceutical Sciences and Pharmacogenomics Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA
| | - Cyril O Y Fong
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94107, USA
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94107, USA
| | - Henry VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94107, USA
| | - Youngho Seo
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94107, USA
| | - Isha H Jain
- Gladstone Institutes, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA.
| |
Collapse
|
3
|
Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Parker MFL, Blecha JE, Drake CR, VanBrocklin HF, Garrido-Ruiz D, Jacobson MP, Aggarwal R, Behr SC, Flavell RR, Wilson DM, Seo Y, Evans MJ. The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (±)- 11C-YJH08 PET. J Nucl Med 2021; 62:723-731. [PMID: 32887758 DOI: 10.2967/jnumed.120.249755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 08/06/2020] [Indexed: 11/16/2022] Open
Abstract
Noninvasive methods to study glucocorticoid receptor (GR) signaling are urgently needed to elaborate the complexity of GR signaling in normal physiology and human disorders, as well as to identify selective GR modulators to treat diseases. Here, we report evidence supporting translational studies with (±)-11C-5-(4-fluorobenzyl)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]-quinoline ((±)-11C-YJH08), a radioligand for PET that engages the ligand binding domain on GR. Methods: (±)-11C-YJH08 was synthesized by reacting the phenol precursor with 11C-methyl iodide. The biodistribution was studied in vivo. Specific binding was tested in vivo with adrenalectomy and ligand competition. A library of analogs was synthesized and studied in vitro and in vivo to understand the (±)-11C-YJH08 structure-activity relationship. Rodent dosimetry studies were performed to estimate the human-equivalent doses of (±)-11C-YJH08. Results: (±)-11C-YJH08 was synthesized by reaction of the phenolic precursor with 11C-methyl iodide, giving a radiochemical yield of 51.7% ± 4.7% (decay-corrected to starting 11C-methyl iodide). Specific binding was observed in many tissues, including the brain. An analysis of the (±)-YJH08 structure-activity relationship showed that (R)- and (S)-enantiomers are equally avid for GR by occupying discrete binding modes. A focused chemical screen revealed that the aryl fluoride motif on YJH08 is essential for high-affinity GR binding in vitro, high tissue uptake in vivo, and efficient passage across the blood-brain barrier. Lastly, we performed dosimetry studies on rodents, from which we estimated the human-equivalent doses of (±)-11C-YJH08 to be commensurate with the widely used 11C and 18F tracers. Conclusion: These studies reveal the molecular determinants of a high-affinity and high-selectivity ligand-receptor interaction and support the use of (±)-11C-YJH08 PET to make the first measurements of GR expression in human subjects.
Collapse
Affiliation(s)
- Yangjie Huang
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Ning Zhao
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Yung-Hua Wang
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Charles Truillet
- Imagerie Moleculaire in Vivo, INSERM, CEA, Université Paris Sud, CNRS, Universite Paris Saclay, CEA-Service Hospitalier Frederic Joliot, Orsay, France
| | - Junnian Wei
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Matthew F L Parker
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | | | - Henry F VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.,Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
| | - Diego Garrido-Ruiz
- Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California; and
| | - Matthew P Jacobson
- Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California; and
| | - Rahul Aggarwal
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.,Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, California
| | - Spencer C Behr
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Robert R Flavell
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.,Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
| | - David M Wilson
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Youngho Seo
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.,Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
| | - Michael J Evans
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California .,Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.,Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California; and
| |
Collapse
|
4
|
Beckford-Vera DR, Gonzalez-Junca A, Janneck JS, Huynh TL, Blecha JE, Seo Y, Li X, VanBrocklin HF, Franc BL. PET/CT Imaging of Human TNFα Using [ 89Zr]Certolizumab Pegol in a Transgenic Preclinical Model of Rheumatoid Arthritis. Mol Imaging Biol 2021; 22:105-114. [PMID: 31065895 DOI: 10.1007/s11307-019-01363-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
PURPOSE Tumor necrosis factor alpha (TNFα) drives inflammation and bone degradation in patients with rheumatoid arthritis (RA). Some RA patients experience a rapid clinical response to TNFα inhibitors such as certolizumab pegol (CZP) while other patients show limited to no response. Current methods for imaging RA have limited sensitivity and do not assist in the selection of patients most likely to respond to immune-mediated therapy. Herein, we developed a novel positron emission tomography (PET) radiotracer for immuno-PET imaging of TNFα in transgenic human TNFα-expressing mice. PROCEDURES CZP was modified with p-isothiocyanatobenzyl-deferoxamine (DFO) and radiolabeled with Zr-89. The biological activity of [89Zr]DFO-CZP was evaluated by HPLC and binding assay using human recombinant TNFα (hTNFα). The feasibility of specific immuno-PET imaging of human TNFα was assessed in a transgenic mouse model of RA that expresses human TNFα. This model resembles the progression of RA in humans by maintaining lower levels of circulating hTNFα and exhibits chronic arthritis in the forepaw and hind paw joints. The dosimetry of [89Zr]DFO-CZP in humans was estimated using microPET/CT imaging in Sprague Dawley rats. RESULTS [89Zr]DFO-CZP was isolated with radiolabeling yields of 85 ± 6 % (n = 5) and specific activities ranging from 74 to 185 MBq/mg (n = 5). Following size exclusion purification, the radiochemical purity of [89Zr]DFO-CZP was greater than 97 %. [89Zr]DFO-CZP retained high immunoreactivity with more than 95 % of the radioactivity shifted into higher molecular weight complexes. Images showed increasing uptake of the tracer in forepaw and hind paw joints with disease progression. No uptake was observed in the model previously administered with an excess amount of unmodified CZP and in normal control mice, demonstrating in vivo specific uptake of [89Zr]DFO-CZP. CONCLUSION The feasibility of immuno-PET imaging of human TNFα with [89Zr]DFO-CZP has been demonstrated in a preclinical model of RA.
Collapse
Affiliation(s)
- Denis R Beckford-Vera
- Department of Radiology and Molecular Imaging, University of California San Francisco, 185 Berry St., Suite 350, San Francisco, CA, 94107, USA.
| | - Alba Gonzalez-Junca
- Department of Radiation Oncology, University of California San Francisco, 2340 Sutter St., San Francisco, CA, 94115, USA
| | - Jessica S Janneck
- Department of Radiology and Molecular Imaging, University of California San Francisco, 185 Berry St., Suite 350, San Francisco, CA, 94107, USA
| | - Tony L Huynh
- Department of Radiology and Molecular Imaging, University of California San Francisco, 185 Berry St., Suite 350, San Francisco, CA, 94107, USA
| | - Joseph E Blecha
- Department of Radiology and Molecular Imaging, University of California San Francisco, 185 Berry St., Suite 350, San Francisco, CA, 94107, USA
| | - Youngho Seo
- Department of Radiology and Molecular Imaging, University of California San Francisco, 185 Berry St., Suite 350, San Francisco, CA, 94107, USA
| | - Xiaojuan Li
- Department of Radiology and Molecular Imaging, University of California San Francisco, 185 Berry St., Suite 350, San Francisco, CA, 94107, USA
| | - Henry F VanBrocklin
- Department of Radiology and Molecular Imaging, University of California San Francisco, 185 Berry St., Suite 350, San Francisco, CA, 94107, USA
| | - Benjamin L Franc
- Department of Radiology and Molecular Imaging, University of California San Francisco, 185 Berry St., Suite 350, San Francisco, CA, 94107, USA
| |
Collapse
|
5
|
Hayes TR, Chao CK, Blecha JE, Huynh TL, Zinn KR, Thompson CM, Gerdes JM, VanBrocklin HF. Biological Distribution and Metabolic Profiles of Carbon-11 and Fluorine-18 Tracers of VX- and Sarin-Analogs in Sprague-Dawley Rats. Chem Res Toxicol 2020; 34:63-69. [PMID: 33373198 PMCID: PMC7818893 DOI: 10.1021/acs.chemrestox.0c00237] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Organophosphorus esters (OPs) were originally developed as pesticides but were repurposed as easily manufactured, inexpensive, and highly toxic chemical warfare agents. Acute OP toxicity is primarily due to inhibition of acetylcholinesterase (AChE), an enzyme in the central and peripheral nervous system. OP inhibition of AChE can be reversed using oxime reactivators but many show poor CNS penetration, indicating a need for new clinically viable reactivators. However, challenges exist on how to best measure restored AChE activity in vivo and assess the reactivating agent efficacy. This work reports the development of molecular imaging tools using radiolabeled OP analog tracers that are less toxic to handle in the laboratory, yet inhibit AChE in a similar fashion to the actual OPs. Carbon-11 and fluorine-18 radiolabeled analog tracers of VX and sarin OP agents were prepared. Following intravenous injection in normal Sprague-Dawley rats (n = 3-4/tracer), the tracers were evaluated and compared using noninvasive microPET/CT imaging, biodistribution assay, and arterial blood analyses. All showed rapid uptake and stable retention in brain, heart, liver, and kidney tissues determined by imaging and biodistribution. Lung uptake of the sarin analog tracers was elevated, 2-fold and 4-fold higher uptake at 5 and 30 min, respectively, compared to that for the VX analog tracers. All tracers rapidly bound to red blood cells (RBC) and blood proteins as measured in the biodistribution and arterial blood samples. Analysis of the plasma soluble activity (nonprotein/cell bound activity) showed only 1-6% parent tracer and 88-95% of the activity in the combined solid fractions (RBC and protein bound) as early as 0.5 min post injection. Multivariate analysis of tracer production yield, molar activity, brain uptake, brain area under the curve over 0-15 min, and the amount of parent tracer in the plasma at 5 min revealed the [18F]VX analog tracer had the most favorable values for each metric. This tracer was considered the more optimal tracer relative to the other tracers studied and suitable for future in vivo OP exposure and reactivation studies.
Collapse
Affiliation(s)
- Thomas R Hayes
- Department of Radiology and Biomedical Imaging, University of California at San Francisco, San Francisco, California 94143, United States
| | - Chih-Kai Chao
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana 59812, United States
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging, University of California at San Francisco, San Francisco, California 94143, United States
| | - Tony L Huynh
- Department of Radiology and Biomedical Imaging, University of California at San Francisco, San Francisco, California 94143, United States
| | - Kurt R Zinn
- Departments of Radiology, Small Animal Clinical Sciences, and Biomedical Engineering; Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, United States
| | - Charles M Thompson
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana 59812, United States
| | - John M Gerdes
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana 59812, United States
| | - Henry F VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California at San Francisco, San Francisco, California 94143, United States
| |
Collapse
|
6
|
Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Blecha JE, VanBrocklin HF, Seo Y, Sayeed M, Feldman BJ, Aggarwal R, Behr SC, Shao H, Wilson DM, Villanueva-Meyer JE, Gestwicki JE, Evans MJ. A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography. ACS Chem Biol 2020; 15:1381-1391. [PMID: 32255605 PMCID: PMC8031368 DOI: 10.1021/acschembio.9b01043] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
![]()
The
complexity of glucocorticoid receptor (GR) signaling cannot
be measured with direct tissue analysis in living subjects, which
has stifled our understanding of GR’s role in human physiology
or disease and impeded the development of selective GR modulators.
Herein, we report 18F-5-(4-fluorobenzyl)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline (18F-YJH08), a radioligand that enables
noninvasive measurements of tissue autonomous GR expression levels in vivo with positron emission tomography (PET). YJH08 potently
binds GR (Ki ∼ 0.4 nM) with ∼100-fold
selectivity compared to nuclear hormone receptors in the same subfamily. 18F-YJH08 was prepared via Cu(OTf)2(py)4-mediated radiofluorination of an arylboronic acid
pinacol ester with ∼12% decay corrected radiochemical yield
from the starting 18F-fluoride ion. We applied treatment
with the tissue-wide GR agonist dexamethasone and adrenalectomy and
generated an adipocyte specific GR knockout mouse to show that 18F-YJH08 specifically binds GR in normal mouse tissues, including
those for which aberrant GR expression is thought to drive severe
diseases (e.g., brain, adipose tissue, kidneys). Remarkably, 18F-YJH08 PET also revealed that JG231, a potent and bioavailable
HSP70 inhibitor, selectively degrades GR only in the adipose tissue
of mice, a finding that foreshadows how GR targeted PET might be integrated
into drug discovery to screen for selective GR modulation at the tissue
level, beyond the historical screening that was performed at the transcriptional
level. In summary, 18F-YJH08 enables a quantitative assessment
of GR expression levels in real time among multiple tissues simultaneously,
and this technology is a first step toward unraveling the daunting
complexity of GR signaling and rationally engineering tissue specific
therapeutic modulators in vivo.
Collapse
Affiliation(s)
- Yangjie Huang
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94158, United States
| | - Ning Zhao
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94158, United States
| | - Yung-hua Wang
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94158, United States
| | - Charles Truillet
- Imagerie Moleculaire in Vivo, INSERM, CEA, Université Paris Sud, CNRS, Universite Paris Saclay, CEA-Service Hospitalier Frederic Joliot, Orsay 94100, France
| | - Junnian Wei
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94158, United States
| | - Joseph E. Blecha
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94158, United States
| | - Henry F. VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94158, United States
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94158, United States
| | - Youngho Seo
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94158, United States
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94158, United States
| | - Mohd Sayeed
- Department of Pediatrics, University of California San Francisco, San Francisco, California 94158, United States
| | - Brian J. Feldman
- Department of Pediatrics, University of California San Francisco, San Francisco, California 94158, United States
| | - Rahul Aggarwal
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94158, United States
- Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, California 94158, United States
| | - Spencer C. Behr
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94158, United States
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94158, United States
| | - Hao Shao
- Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California 94158, United States
| | - David M. Wilson
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94158, United States
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94158, United States
| | - Javier E. Villanueva-Meyer
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94158, United States
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94158, United States
| | - Jason E. Gestwicki
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94158, United States
- Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California 94158, United States
| | - Michael J. Evans
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94158, United States
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94158, United States
- Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California 94158, United States
| |
Collapse
|
7
|
Hayes TR, Blecha JE, Chao CK, Huynh TL, VanBrocklin HF, Zinn KR, Taylor PW, Gerdes JM, Thompson CM. Positron emission tomography evaluation of oxime countermeasures in live rats using the tracer O-(2-[ 18 F]fluoroethyl)-O-(p-nitrophenyl)methylphosphonate [ 18 F]-VXS. Ann N Y Acad Sci 2020; 1479:180-195. [PMID: 32436233 DOI: 10.1111/nyas.14363] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2020] [Revised: 04/13/2020] [Accepted: 04/17/2020] [Indexed: 11/27/2022]
Abstract
Oxime antidotes regenerate organophosphate-inhibited acetylcholinesterase (AChE). Although they share a common mechanism of AChE reactivation, the rate and amount of oxime that enters the brain are critical to the efficacy, a process linked to the oxime structure and charge. Using a platform based on the organophosphate [18 F]-VXS as a positron emission tomography tracer for active AChE, the in vivo distribution of [18 F]-VXS was evaluated after an LD50 dose (250 μg/kg) of the organophosphate paraoxon (POX) and following oximes as antidotes. Rats given [18 F]-VXS tracer alone had significantly higher radioactivity (two- to threefold) in the heart and lung than rats given LD50 POX at 20 or 60 min prior to [18 F]-VXS. When rats were given LD50 POX followed by 2-PAM (cationic), RS194b (ionizable), or monoisonitrosoacetone (MINA) (neutral), central nervous system (CNS) radioactivity returned to levels at or above untreated naive rats (no POX), whereas CNS radioactivity did not increase in rats given the dication oximes HI-6 or MMB-4. MINA showed a significant, pairwise increase in CNS brain radioactivity compared with POX-treated rats. This new in vivo dynamic platform using [18 F]-VXS tracer measures and quantifies peripheral and CNS relative changes in AChE availability after POX exposure and is suitable for comparing oxime delivery and AChE reactivation in rats.
Collapse
Affiliation(s)
- Thomas R Hayes
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California
| | - Chih-Kai Chao
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana
| | - Tony L Huynh
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California
| | - Henry F VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California
| | - Kurt R Zinn
- Departments of Radiology, Small Animal Clinical Sciences, and Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan
| | - Palmer W Taylor
- Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, California
| | - John M Gerdes
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana
| | - Charles M Thompson
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana
| |
Collapse
|
8
|
Kalita M, Parker MFL, Luu JM, Stewart MN, Blecha JE, VanBrocklin HF, Evans MJ, Flavell RR, Rosenberg OS, Ohliger MA, Wilson DM. Arabinofuranose-derived positron-emission tomography radiotracers for detection of pathogenic microorganisms. J Labelled Comp Radiopharm 2020; 63:231-239. [PMID: 32222086 DOI: 10.1002/jlcr.3835] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 02/06/2020] [Accepted: 02/26/2020] [Indexed: 12/16/2022]
Abstract
PURPOSE Detection of bacteria-specific metabolism via positron emission tomography (PET) is an emerging strategy to image human pathogens, with dramatic implications for clinical practice. In silico and in vitro screening tools have recently been applied to this problem, with several monosaccharides including l-arabinose showing rapid accumulation in Escherichia coli and other organisms. Our goal for this study was to evaluate several synthetically viable arabinofuranose-derived 18 F analogs for their incorporation into pathogenic bacteria. PROCEDURES We synthesized four radiolabeled arabinofuranose-derived sugars: 2-deoxy-2-[18 F]fluoro-arabinofuranoses (d-2-18 F-AF and l-2-18 F-AF) and 5-deoxy-5-[18 F]fluoro-arabinofuranoses (d-5-18 F-AF and l-5-18 F-AF). The arabinofuranoses were synthesized from 18 F- via triflated, peracetylated precursors analogous to the most common radiosynthesis of 2-deoxy-2-[18 F]fluoro-d-glucose ([18 F]FDG). These radiotracers were screened for their uptake into E. coli and Staphylococcus aureus. Subsequently, the sensitivity of d-2-18 F-AF and l-2-18 F-AF to key human pathogens was investigated in vitro. RESULTS All 18 F radiotracer targets were synthesized in high radiochemical purity. In the screening study, d-2-18 F-AF and l-2-18 F-AF showed greater accumulation in E. coli than in S. aureus. When evaluated in a panel of pathologic microorganisms, both d-2-18 F-AF and l-2-18 F-AF demonstrated sensitivity to most gram-positive and gram-negative bacteria. CONCLUSIONS Arabinofuranose-derived 18 F PET radiotracers can be synthesized with high radiochemical purity. Our study showed absence of bacterial accumulation for 5-substitued analogs, a finding that may have mechanistic implications for related tracers. Both d-2-18 F-AF and l-2-18 F-AF showed sensitivity to most gram-negative and gram-positive organisms. Future in vivo studies will evaluate the diagnostic accuracy of these radiotracers in animal models of infection.
Collapse
Affiliation(s)
- Mausam Kalita
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Matthew F L Parker
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Justin M Luu
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Megan N Stewart
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Henry F VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Michael J Evans
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Robert R Flavell
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| | - Oren S Rosenberg
- Department of Medicine, University of California San Francisco, San Francisco, California
| | - Michael A Ohliger
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.,Department of Radiology, Zuckerberg San Francisco General Hospital, San Francisco, California
| | - David M Wilson
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| |
Collapse
|
9
|
Stewart MN, Parker MFL, Jivan S, Luu JM, Huynh TL, Schulte B, Seo Y, Blecha JE, Villanueva-Meyer JE, Flavell RR, VanBrocklin HF, Ohliger MA, Rosenberg O, Wilson DM. High Enantiomeric Excess In-Loop Synthesis of d-[methyl- 11C]Methionine for Use as a Diagnostic Positron Emission Tomography Radiotracer in Bacterial Infection. ACS Infect Dis 2020; 6:43-49. [PMID: 31697062 DOI: 10.1021/acsinfecdis.9b00196] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Currently, there exists no accurate, noninvasive clinical imaging method to detect living bacteria in vivo. Our goal is to provide a positron emission tomography (PET) method to image infection by targeting bacteria-specific metabolism. Standard of care methodologies detect morphologic changes, image immunologic response to infection, or employ invasive tissue sampling with associated patient morbidity. These strategies, however, are not specific for living bacteria and are often inadequate to detect bacterial infection during fever workup. As such, there is an unmet clinical need to identify and validate new imaging tools suitable for noninvasive, in vivo (PET) imaging of living bacteria. We have shown that d-[methyl-11C]methionine (d-[11C]Met) can distinguish active bacterial infection from sterile inflammation in a murine infection model and is sensitive to both Gram-positive and Gram-negative bacteria. Here, we report an automated and >99% enantiomeric excess (ee) synthesis of d-[11C]Met from a linear d-homocysteine precursor, a significant improvement over the previously reported synthesis utilizing a d-homocysteine thiolactone hydrochloride precursor with approximately 75-85% ee. Furthermore, we took additional steps toward applying d-[11C]Met to infected patients. d-[11C]Met was subject to a panel of clinically relevant bacterial strains and demonstrated promising sensitivity to these pathogens. Finally, we performed radiation dosimetry in a normal murine cohort to set the stage for translation to humans in the near future.
Collapse
Affiliation(s)
- Megan N. Stewart
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94107, United States
| | - Matthew F. L. Parker
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94107, United States
| | - Salma Jivan
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94107, United States
| | - Justin M. Luu
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94107, United States
| | - Tony L. Huynh
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94107, United States
| | - Brailee Schulte
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94107, United States
| | - Youngho Seo
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94107, United States
| | - Joseph E. Blecha
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94107, United States
| | - Javier E. Villanueva-Meyer
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94107, United States
| | - Robert R. Flavell
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94107, United States
| | - Henry F. VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94107, United States
| | - Michael A. Ohliger
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94107, United States
| | - Oren Rosenberg
- Department of Medicine, University of California, San Francisco, San Francisco California 94158, United States
| | - David M. Wilson
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94107, United States
| |
Collapse
|
10
|
Wang S, Blaha C, Santos R, Huynh T, Hayes TR, Beckford-Vera DR, Blecha JE, Hong AS, Fogarty M, Hope TA, Raleigh DR, Wilson DM, Evans MJ, VanBrocklin HF, Ozawa T, Flavell RR. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy. Mol Pharm 2019; 16:3831-3841. [PMID: 31381351 DOI: 10.1021/acs.molpharmaceut.9b00464] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Boron neutron capture therapy (BNCT) is a therapeutic modality which has been used for the treatment of cancers, including brain and head and neck tumors. For effective treatment via BNCT, efficient and selective delivery of a high boron dose to cancer cells is needed. Prostate-specific membrane antigen (PSMA) is a target for prostate cancer imaging and drug delivery. In this study, we conjugated boronic acid or carborane functional groups to a well-established PSMA inhibitor scaffold to deliver boron to prostate cancer cells and prostate tumor xenograft models. Eight boron-containing PSMA inhibitors were synthesized. All of these compounds showed a strong binding affinity to PSMA in a competition radioligand binding assay (IC50 from 555.7 to 20.3 nM). Three selected compounds 1a, 1d, and 1f were administered to mice, and their in vivo blocking of 68Ga-PSMA-11 uptake was demonstrated through a positron emission tomography (PET) imaging and biodistribution experiment. Biodistribution analysis demonstrated boron uptake of 4-7 μg/g in 22Rv1 prostate xenograft tumors and similar tumor/muscle ratios compared to the ratio for the most commonly used BNCT compound, 4-borono-l-phenylalanine (BPA). Taken together, these data suggest a potential role for PSMA targeted BNCT agents in prostate cancer therapy following suitable optimization.
Collapse
Affiliation(s)
- Sinan Wang
- Department of Radiology and Biomedical Imaging , University of California , San Francisco , California , United States
| | - Charles Blaha
- Department of Bioengineering and Therapeutic Sciences , University of California , San Francisco , California , United States
| | - Raquel Santos
- Department of Neurological Surgery , University of California , San Francisco , California , United States
| | - Tony Huynh
- Department of Radiology and Biomedical Imaging , University of California , San Francisco , California , United States
| | - Thomas R Hayes
- Department of Radiology and Biomedical Imaging , University of California , San Francisco , California , United States
| | - Denis R Beckford-Vera
- Department of Radiology and Biomedical Imaging , University of California , San Francisco , California , United States
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging , University of California , San Francisco , California , United States
| | - Andrew S Hong
- Department of Radiology and Biomedical Imaging , University of California , San Francisco , California , United States
| | - Miko Fogarty
- Department of Neurological Surgery , University of California , San Francisco , California , United States
| | - Thomas A Hope
- Department of Radiology and Biomedical Imaging , University of California , San Francisco , California , United States
| | - David R Raleigh
- Department of Neurological Surgery , University of California , San Francisco , California , United States.,Departments of Radiation Oncology , University of California , San Francisco , California , United States
| | - David M Wilson
- Department of Radiology and Biomedical Imaging , University of California , San Francisco , California , United States
| | - Michael J Evans
- Department of Radiology and Biomedical Imaging , University of California , San Francisco , California , United States
| | - Henry F VanBrocklin
- Department of Radiology and Biomedical Imaging , University of California , San Francisco , California , United States
| | - Tomoko Ozawa
- Department of Neurological Surgery , University of California , San Francisco , California , United States
| | - Robert R Flavell
- Department of Radiology and Biomedical Imaging , University of California , San Francisco , California , United States.,Department of Pharmaceutical Chemistry , University of California , San Francisco , California , United States
| |
Collapse
|
11
|
Hayes TR, Blecha JE, Thompson CM, Gerdes JM, VanBrocklin HF. Divergent synthesis of organophosphate [ 11C]VX- and [ 11C]Sarin-surrogates from a common set of starting materials. Appl Radiat Isot 2019; 151:182-186. [PMID: 31202183 DOI: 10.1016/j.apradiso.2019.05.033] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2019] [Revised: 05/09/2019] [Accepted: 05/23/2019] [Indexed: 11/27/2022]
Abstract
Radiolabeled 1-[11C]ethyl, 4-nitrophenyl methylphosphonate (VX surrogate) and 2-[11C]-propanyl, 4-nitrophenyl methylphosphonate (sarin surrogate) were developed as organophosphate (OP) tracers. The [11C]ethyl- and [11C]isopropyl-iodide radiolabeled synthons were obtained by temperature controlled, in loop reactions of [11C]CO2 with MeMgBr followed by reduction with LiAlH4, then reaction with HI. Distillation of the [11C]alkyl iodides into a solution of hydrogen (4-nitrophenyl)methylphosphonate and cesium carbonate afforded the desired tracers in >95% radiochemical purity, yields from [11C]CO2 of 1-3% and 1.7-15.1 GBq/mmol molar activities.
Collapse
Affiliation(s)
- Thomas R Hayes
- Department of Radiology and Biomedical Imaging, University of California - San Francisco, 185 Berry St. Suite 350, San Francisco, CA, 94107, United States
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging, University of California - San Francisco, 185 Berry St. Suite 350, San Francisco, CA, 94107, United States
| | - Charles M Thompson
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, 59812, United States
| | - John M Gerdes
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, 59812, United States
| | - Henry F VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California - San Francisco, 185 Berry St. Suite 350, San Francisco, CA, 94107, United States.
| |
Collapse
|
12
|
Levi J, Lam T, Goth SR, Yaghoubi S, Bates J, Ren G, Jivan S, Huynh TL, Blecha JE, Khattri R, Schmidt KF, Jennings D, VanBrocklin H. Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy. Cancer Res 2019; 79:3455-3465. [PMID: 31064845 DOI: 10.1158/0008-5472.can-19-0267] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 03/12/2019] [Accepted: 05/01/2019] [Indexed: 12/29/2022]
Abstract
Compelling evidence points to immune cell infiltration as a critical component of successful immunotherapy. However, there are currently no clinically available, noninvasive methods capable of evaluating immune contexture prior to or during immunotherapy. In this study, we evaluate a T-cell-specific PET agent, [18F]F-AraG, as an imaging biomarker predictive of response to checkpoint inhibitor therapy. We determined the specificity of the tracer for activated T cells in vitro and in a virally induced model of rhabdomyosarcoma. Of all immune cells tested, activated human CD8+ effector cells showed the highest accumulation of [18F]F-AraG. Isolation of lymphocytes from the rhabdomyosarcoma tumors showed that more than 80% of the intratumoral signal came from accumulation of [18F]F-AraG in immune cells, primarily CD8+ and CD4+. Longitudinal monitoring of MC38 tumor-bearing mice undergoing anti-PD-1 treatment revealed differences in signal between PD-1 and isotype antibody-treated mice early into treatment. The differences in [18F]F-AraG signal were also apparent between responders and nonresponders to anti-PD-1 therapy. Importantly, we found that the signal in the tumor-draining lymph nodes provides key information about response to anti-PD-1 therapy. Overall, [18F]F-AraG has potential to serve as a much needed immunomonitoring clinical tool for timely evaluation of immunotherapy. SIGNIFICANCE: These findings reveal differences in T-cell activation between responders and nonresponders early into anti-PD-1 treatment, which may impact many facets of immuno-oncology, including patient selection, management, and development of novel combinatorial approaches.
Collapse
Affiliation(s)
- Jelena Levi
- CellSight Technologies Incorporated, San Francisco, California.
| | - Tina Lam
- CellSight Technologies Incorporated, San Francisco, California
| | - Samuel R Goth
- CellSight Technologies Incorporated, San Francisco, California
| | | | - Jennifer Bates
- CellSight Technologies Incorporated, San Francisco, California
| | - Gang Ren
- CellSight Technologies Incorporated, San Francisco, California
| | - Salma Jivan
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
| | - Tony L Huynh
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
| | | | | | | | - Henry VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
| |
Collapse
|
13
|
Neumann KD, Blecha JE, Hayes TR, Huynh T, Chao CK, Guilloteau N, Zinn KR, VanBrocklin HF, Thompson CM, Gerdes JM. Radiosynthesis, ex Vivo Biodistribution, and in Vivo Positron Emission Tomography Imaging Evaluations of [ 11C]2-Pyridinealdoxime Methiodide ([ 11C]2-PAM): A First-In-Class Antidote Tracer for Organophosphate Intoxication. ACS Chem Neurosci 2018; 9:3007-3014. [PMID: 30071719 DOI: 10.1021/acschemneuro.8b00212] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
2-Pyridinealdoxime methiodide (2-PAM) is a widely used antidote for the treatment of organophosphorus (OP) exposure that reactivates the target protein acetylcholinesterase. Carbon-11 2-PAM was prepared to more fully understand the in vivo mode of action, distribution, and dynamic qualities of this important countermeasure. Alkylation of 2-pyridinealdoxime with [11C]CH3I provided the first-in-class [11C]2-PAM tracer in 3.5% decay corrected radiochemical yield from [11C]CH3I, >99% radiochemical purity, and 4831 Ci/mmol molar activity. [11C]2-PAM tracer distribution was evaluated by ex vivo biodistribution and in vivo dynamic positron emission tomography (PET) imaging in naïve (OP exposure deficient) rats. Tracer alone and tracer coinjected with a body mass-scaled human therapeutic dose of 30 mg/kg nonradioactive 2-PAM demonstrated statistically similar tissue and blood distribution profiles with the greatest uptake in kidney and significantly lower levels in liver, heart, and lung with lesser amounts in blood and brain. The imaging and biodistribution data show that radioactivity uptake in brain and peripheral organs is rapid and characterized by differential tissue radioactivity washout profiles. Analysis of arterial blood samples taken 5 min after injection showed ∼82% parent [11C]2-PAM tracer. The imaging and biodistribution data are now established, enabling future comparisons to outcomes acquired in OP intoxicated rodent models.
Collapse
Affiliation(s)
- Kiel D. Neumann
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States
| | - Joseph E. Blecha
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States
| | - Thomas R. Hayes
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States
| | - Tony Huynh
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States
| | - Chih-Kai Chao
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana 59812, United States
| | - Nicolas Guilloteau
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana 59812, United States
| | - Kurt R. Zinn
- Departments of Radiology and Biomedical Engineering, Michigan State University, East Lansing, Michigan 48824, United States
| | - Henry F. VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94143, United States
| | - Charles M. Thompson
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana 59812, United States
| | - John M. Gerdes
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana 59812, United States
| |
Collapse
|
14
|
Hayes TR, Thompson CM, Blecha JE, Gerdes JM, VanBrocklin HF. Radiosynthesis of O-(1-[ 18 F]fluoropropan-2-yl)-O-(4-nitrophenyl)methylphosphonate: A novel PET tracer surrogate of sarin. J Labelled Comp Radiopharm 2018; 61:1089-1094. [PMID: 30347484 DOI: 10.1002/jlcr.3688] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2018] [Revised: 10/05/2018] [Accepted: 10/15/2018] [Indexed: 11/09/2022]
Abstract
O-(1-Fluoropropan-2-yl)-O-(4-nitrophenyl) methylphosphonate is a reactive organophosphate ester (OP) developed as a surrogate of the chemical warfare agent sarin that forms a similar covalent adduct at the active site serine of acetylcholinesterase. The radiolabeled O-(1-[18 F]fluoropropan-2-yl)-O-(4-nitrophenyl) methylphosphonate ([18 F] fluorosarin surrogate) has not been previously prepared. In this paper, we report the first radiosynthesis of this tracer from the reaction of bis-(4-nitrophenyl) methylphosphonate with 1-[18 F]fluoro-2-propanol in the presence of DBU. The 1-[18 F]fluoro-2-propanol was prepared by reaction of propylene sulfite with Kryptofix 2.2.2 and [18 F] fluoride ion. The desired tracer O-(1-[18 F]fluoropropan-2-yl)-O-(4-nitrophenyl) methylphosphonate was obtained in a >98% radiochemical purity with a 2.4% ± 0.6% yield (n = 5, 65 minutes from start of synthesis) based on starting [18 F] fluoride ion and a molar activity of 49.9 GBq/μmol (1.349 ± 0.329 Ci/μmol, n = 3). This new facile radiosynthesis routinely affords sufficient quantities of [18 F] fluorosarin surrogate in high radiochemical purity, which will further enable the tracer development as a novel radiolabeled OP acetylcholinesterase inhibitor for assessment of OP modes of action with PET imaging in vivo.
Collapse
Affiliation(s)
- Thomas R Hayes
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA
| | - Charles M Thompson
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, USA
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA
| | - John M Gerdes
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, USA
| | - Henry F VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA
| |
Collapse
|
15
|
Taglang C, Korenchan DE, von Morze C, Yu J, Najac C, Wang S, Blecha JE, Subramaniam S, Bok R, VanBrocklin HF, Vigneron DB, Ronen SM, Sriram R, Kurhanewicz J, Wilson DM, Flavell RR. Late-stage deuteration of 13C-enriched substrates for T 1 prolongation in hyperpolarized 13C MRI. Chem Commun (Camb) 2018; 54:5233-5236. [PMID: 29726563 PMCID: PMC6054790 DOI: 10.1039/c8cc02246a] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A robust and selective late-stage deuteration methodology was applied to 13C-enriched amino and alpha hydroxy acids to increase spin-lattice relaxation constant T1 for hyperpolarized 13C magnetic resonance imaging. For the five substrates with 13C-labeling on the C1-position ([1-13C]alanine, [1-13C]serine, [1-13C]lactate, [1-13C]glycine, and [1-13C]valine), significant increase of their T1 was observed at 3 T with deuterium labeling (+26%, 22%, +16%, +25% and +29%, respectively). Remarkably, in the case of [2-13C]alanine, [2-13C]serine and [2-13C]lactate, deuterium labeling led to a greater than four fold increase in T1. [1-13C,2-2H]alanine, produced using this method, was applied to in vitro enzyme assays with alanine aminotransferase, demonstrating a kinetic isotope effect.
Collapse
Affiliation(s)
- Céline Taglang
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - David E. Korenchan
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - Cornelius von Morze
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - Justin Yu
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - Chloé Najac
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - Sinan Wang
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - Joseph E. Blecha
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - Sukumar Subramaniam
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - Robert Bok
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - Henry F. VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - Daniel B. Vigneron
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - Sabrina M. Ronen
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - Renuka Sriram
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - John Kurhanewicz
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - David M. Wilson
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| | - Robert R. Flavell
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA.
| |
Collapse
|
16
|
Blecha JE, Henderson BD, Hockley BG, VanBrocklin HF, Zubieta JK, DaSilva AF, Kilbourn MR, Koeppe RA, Scott PJ, Shao X. An updated synthesis of [ 11 C]carfentanil for positron emission tomography (PET) imaging of the μ-opioid receptor. J Labelled Comp Radiopharm 2017; 60:375-380. [PMID: 28419528 PMCID: PMC9886010 DOI: 10.1002/jlcr.3513] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2017] [Revised: 04/10/2017] [Accepted: 04/11/2017] [Indexed: 02/01/2023]
Abstract
[11 C]Carfentanil ([11 C]CFN) is a selective radiotracer for in vivo positron emission tomography imaging studies of the μ-opioid system that, in our laboratories, is synthesized by methylation of the corresponding carboxylate precursor with [11 C]MeOTf, and purified using a C2 solid-phase extraction cartridge. Changes in the commercial availability of common C2 cartridges have necessitated future proofing the synthesis of [11 C]CFN to maintain reliable delivery of the radiotracer for clinical imaging studies. An updated synthesis of [11 C]CFN is reported that replaces a now obsolete purification cartridge with a new commercially available version and also substitutes the organic solvents used in traditional production methods with ethanol.
Collapse
Affiliation(s)
- Joseph E. Blecha
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA
| | | | - Brian G. Hockley
- Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Henry F. VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA
| | - Jon-Kar Zubieta
- Department of Psychiatry, University Neuropsychiatric Institute, University of Utah Health Center, Salt Lake City, UT, USA
| | - Alexandre F. DaSilva
- Headache and Orofacial Pain Effort, Biologic and Materials Sciences Department, School of Dentistry, University of Michigan, Ann Arbor, MI, USA
| | - Michael R. Kilbourn
- Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Robert A. Koeppe
- Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Peter J.H. Scott
- Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Xia Shao
- Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, USA
| |
Collapse
|
17
|
Neumann KD, Thompson CM, Blecha JE, Gerdes JM, VanBrocklin HF. An improved radiosynthesis of O-(2-[ 18 F]fluoroethyl)-O-(p-nitrophenyl)methylphosphonate: A first-in-class cholinesterase PET tracer. J Labelled Comp Radiopharm 2017; 60:337-342. [PMID: 28406525 DOI: 10.1002/jlcr.3511] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Revised: 03/31/2017] [Accepted: 04/05/2017] [Indexed: 11/06/2022]
Abstract
O-(2-Fluoroethyl)-O-(p-nitrophenyl) methylphosphonate 1 is an organophosphate cholinesterase inhibitor that creates a phosphonyl-serine covalent adduct at the enzyme active site blocking cholinesterase activity in vivo. The corresponding radiolabeled O-(2-[18 F]fluoroethyl)-O-(p-nitrophenyl) methylphosphonate, [18 F]1, has been previously prepared and found to be an excellent positron emission tomography imaging tracer for assessment of cholinesterases in live brain, peripheral tissues, and blood. However, the previously reported [18 F]1 tracer synthesis was slow even with microwave acceleration, required high-performance liquid chromatography separation of the tracer from impurities, and gave less optimal radiochemical yields. In this paper, we report a new synthetic approach to circumvent these shortcomings that is reliant on the facile reactivity of bis-(O,O-p-nitrophenyl) methylphosphonate, 2, with 2-fluoroethanol in the presence of DBU. The cold synthesis was successfully translated to provide a more robust radiosynthesis. Using this new strategy, the desired tracer, [18 F]1, was obtained in a non-decay-corrected radiochemical yield of 8 ± 2% (n = 7) in >99% radiochemical and >95% chemical purity with a specific activity of 3174 ± 345 Ci/mmol (EOS). This new facile radiosynthesis routinely affords highly pure quantities of [18 F]1, which will further enable tracer development of OP cholinesterase inhibitors and their evaluation in vivo.
Collapse
Affiliation(s)
- Kiel D Neumann
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
| | - Charles M Thompson
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, USA
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
| | - John M Gerdes
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, USA
| | - Henry F VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
| |
Collapse
|
18
|
Dannoon S, Ganguly T, Cahaya H, Geruntho JJ, Galliher MS, Beyer SK, Choy CJ, Hopkins MR, Regan M, Blecha JE, Skultetyova L, Drake CR, Jivan S, Barinka C, Jones EF, Berkman CE, VanBrocklin HF. Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J Med Chem 2016; 59:5684-94. [PMID: 27228467 DOI: 10.1021/acs.jmedchem.5b01850] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
A series of phosphoramidate-based prostate specific membrane antigen (PSMA) inhibitors of increasing lipophilicity were synthesized (4, 5, and 6), and their fluorine-18 analogs were evaluated for use as positron emission tomography (PET) imaging agents for prostate cancer. To gain insight into their modes of binding, they were also cocrystallized with the extracellular domain of PSMA. All analogs exhibited irreversible binding to PSMA with IC50 values ranging from 0.4 to 1.3 nM. In vitro assays showed binding and rapid internalization (80-95%, 2 h) of the radiolabeled ligands in PSMA(+) cells. In vivo distribution demonstrated significant uptake in CWR22Rv1 (PSMA(+)) tumor, with tumor to blood ratios of 25.6:1, 63.6:1, and 69.6:1 for [(18)F]4, [(18)F]5, and [(18)F]6, respectively, at 2 h postinjection. Installation of aminohexanoic acid (AH) linkers in the phosphoramidate scaffold improved their PSMA binding and inhibition and was critical for achieving suitable in vivo imaging properties, positioning [(18)F]5 and [(18)F]6 as favorable candidates for future prostate cancer imaging clinical trials.
Collapse
Affiliation(s)
- Shorouk Dannoon
- Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States
| | - Tanushree Ganguly
- Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States
| | - Hendry Cahaya
- Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States
| | - Jonathan J Geruntho
- Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States
| | - Matthew S Galliher
- Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States
| | - Sophia K Beyer
- Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States
| | - Cindy J Choy
- Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States
| | - Mark R Hopkins
- Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States
| | - Melanie Regan
- Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States
| | | | - Christopher R Drake
- Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States
| | - Salma Jivan
- Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States
| | - Cyril Barinka
- Institute of Biotechnology , 252 50 Prague, Czech Republic
| | - Ella F Jones
- Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States
| | - Clifford E Berkman
- Department of Chemistry, Washington State University , Pullman, Washington 99164-4630, United States.,Cancer Targeted Technology , Woodinville, Washington 98072, United States
| | - Henry F VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California-San Francisco , 185 Berry Street, San Francisco, California 94107, United States
| |
Collapse
|
19
|
Flavell RR, von Morze C, Blecha JE, Korenchan DE, Van Criekinge M, Sriram R, Gordon JW, Chen HY, Subramaniam S, Bok RA, Wang ZJ, Vigneron DB, Larson PE, Kurhanewicz J, Wilson DM. Application of Good's buffers to pH imaging using hyperpolarized (13)C MRI. Chem Commun (Camb) 2016; 51:14119-22. [PMID: 26257040 DOI: 10.1039/c5cc05348j] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
N-(2-Acetamido)-2-aminoethanesulfonic acid (ACES), one of Good's buffers, was applied to pH imaging using hyperpolarized (13)C magnetic resonance spectroscopy. Rapid NMR- and MRI-based pH measurements were obtained by exploiting the sensitive pH-dependence of its (13)C chemical shift within the physiologic range.
Collapse
Affiliation(s)
- Robert R Flavell
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94158, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Li L, Che L, Wang C, Blecha JE, Li X, VanBrocklin HF, Calvisi DF, Puchowicz M, Chen X, Seo Y. [(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice. Mol Imaging Biol 2016; 18:360-7. [PMID: 26567114 PMCID: PMC4866912 DOI: 10.1007/s11307-015-0915-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
PURPOSE Altered metabolism, including increased glycolysis and de novo lipogenesis, is one of the hallmarks of cancer. Radiolabeled nutrients, including glucose and acetate, are extensively used for the detection of various tumors, including hepatocellular carcinomas (HCCs). High signal of [(11)C]acetate positron emission tomography (PET) in tumors is often considered to be associated with increased expression of fatty acid synthase (FASN) and increased de novo lipogenesis in tumor tissues. Defining a subset of tumors with increased [(11)C]acetate PET signal and thus increased lipogenesis was suggested to help select a group of patients, who may benefit from lipogenesis-targeting therapies. PROCEDURES To investigate whether [(11)C]acetate PET imaging is truly associated with increased de novo lipogenesis along with hepatocarcinogenesis, we performed [(11)C]acetate PET imaging in wild-type mice as well as two mouse HCC models, induced by myrAKT/Ras(V12) (AKT/Ras) and PIK3CA(1047R)/c-Met (PI3K/Met) oncogene combinations. In addition, we analyzed FASN expression and de novo lipogenesis rate in these mouse liver tissues. RESULTS We found that while HCCs induced by AKT/Ras co-expression showed high levels of [(11)C]acetate PET signal compared to normal liver, HCCs induced by PI3K/Met overexpression did not. Intriguingly, elevated FASN expression and increased de novo lipogenesis rate were observed in both AKT/Ras and PI3K/Met HCCs. CONCLUSION Altogether, our study suggests that [(11)C]acetate PET imaging can be a useful tool for imaging of a subset of HCCs. However, at molecular level, the increased [(11)C]acetate PET imaging is not always associated with increased FASN expression or de novo lipogenesis.
Collapse
Affiliation(s)
- Lei Li
- School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, 94143-0912, USA
| | - Li Che
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, 94143-0912, USA
| | - Chunmei Wang
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, 94143-0912, USA
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
| | - Xiaolei Li
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, 94143-0912, USA
| | - Henry F VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
| | - Diego F Calvisi
- Institute of Pathology, University of Greifswald, Greifswald, Germany
| | - Michelle Puchowicz
- Department of Nutrition, Case Western Reserve University, Cleveland, OH, USA
| | - Xin Chen
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, 94143-0912, USA.
| | - Youngho Seo
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
- Department of Radiation Oncology, University of California, San Francisco, CA, USA.
- UCSF-UC Berkeley Joint Graduate Group in Bioengineering, University of California, San Francisco, CA, USA.
- Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
- UCSF Physics Research Laboratory, Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143-0946, USA.
| |
Collapse
|
21
|
Flavell RR, Truillet C, Regan MK, Ganguly T, Blecha JE, Kurhanewicz J, VanBrocklin HF, Keshari KR, Chang CJ, Evans MJ, Wilson DM. Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography. Bioconjug Chem 2015; 27:170-8. [PMID: 26649808 DOI: 10.1021/acs.bioconjchem.5b00584] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Solid tumors are hypoxic with altered metabolism, resulting in secretion of acids into the extracellular matrix and lower relative pH, a feature associated with local invasion and metastasis. Therapeutic and diagnostic agents responsive to this microenvironment may improve tumor-specific delivery. Therefore, we pursued a general strategy whereby caged small-molecule drugs or imaging agents liberate their parent compounds in regions of low interstitial pH. In this manuscript, we present a new acid-labile prodrug method based on the glycosylamine linkage, and its application to a class of positron emission tomography (PET) imaging tracers, termed [(18)F]FDG amines. [(18)F]FDG amines operate via a proposed two-step mechanism, in which an acid-labile precursor decomposes to form the common radiotracer 2-deoxy-2-[(18)F]fluoro-d-glucose, which is subsequently accumulated by glucose avid cells. The rate of decomposition of [(18)F]FDG amines is tunable in a systematic fashion, tracking the pKa of the parent amine. In vivo, a 4-phenylbenzylamine [(18)F]FDG amine congener showed greater relative accumulation in tumors over benign tissue, which could be attenuated upon tumor alkalinization using previously validated models, including sodium bicarbonate treatment, or overexpression of carbonic anhydrase. This new class of PET tracer represents a viable approach for imaging acidic interstitial pH with potential for clinical translation.
Collapse
Affiliation(s)
- Robert R Flavell
- Department of Radiology and Biomedical Imaging, University of California , San Francisco, California 94158, United States
| | - Charles Truillet
- Department of Radiology and Biomedical Imaging, University of California , San Francisco, California 94158, United States
| | - Melanie K Regan
- Department of Radiology and Biomedical Imaging, University of California , San Francisco, California 94158, United States
| | - Tanushree Ganguly
- Department of Radiology and Biomedical Imaging, University of California , San Francisco, California 94158, United States
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging, University of California , San Francisco, California 94158, United States
| | - John Kurhanewicz
- Department of Radiology and Biomedical Imaging, University of California , San Francisco, California 94158, United States
| | - Henry F VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California , San Francisco, California 94158, United States
| | - Kayvan R Keshari
- Department of Radiology and Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center , New York, New York 10065, United States
| | - Christopher J Chang
- Departments of Chemistry and Molecular and Cell Biology and the Howard Hughes Medical Institute, University of California , Berkeley, California 94720, United States
| | - Michael J Evans
- Department of Radiology and Biomedical Imaging, University of California , San Francisco, California 94158, United States
| | - David M Wilson
- Department of Radiology and Biomedical Imaging, University of California , San Francisco, California 94158, United States
| |
Collapse
|
22
|
Ganguly T, Dannoon S, Hopkins MR, Murphy S, Cahaya H, Blecha JE, Jivan S, Drake CR, Barinka C, Jones EF, VanBrocklin HF, Berkman CE. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nucl Med Biol 2015; 42:780-7. [PMID: 26169882 DOI: 10.1016/j.nucmedbio.2015.06.003] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2015] [Revised: 05/26/2015] [Accepted: 06/03/2015] [Indexed: 10/23/2022]
Abstract
INTRODUCTION In this study, a structurally modified phosphoramidate scaffold, with improved prostate-specific membrane antigen (PSMA) avidity, stability and in vivo characteristics, as a PET imaging agent for prostate cancer (PCa), was prepared and evaluated. METHODS p-Fluorobenzoyl-aminohexanoate and 2-(3-hydroxypropyl)glycine were introduced into the PSMA-targeting scaffold yielding phosphoramidate 5. X-ray crystallography was performed on the PSMA/5 complex. [(18)F]5 was synthesized, and cell uptake and internalization studies were conducted in PSMA(+) LNCaP and CWR22Rv1 cells and PSMA(-) PC-3 cells. In vivo PET imaging and biodistribution studies were performed at 1 and 4 h post injection in mice bearing CWR22Rv1 tumor, with or without blocking agent. RESULTS The crystallographic data showed interaction of the p-fluorobenzoyl group with an arene-binding cleft on the PSMA surface. In vitro studies revealed elevated uptake of [(18)F]5 in PSMA(+) cells (2.2% in CWR22Rv1 and 12.1% in LNCaP) compared to PSMA(-) cells (0.08%) at 4 h. In vivo tumor uptake of 2.33% ID/g and tumor-to-blood ratio of 265:1 was observed at 4 h. CONCLUSIONS We have successfully synthesized, radiolabeled and evaluated a new PSMA-targeted PET agent. The crystal structure of the PSMA/5 complex highlighted the interactions within the arene-binding cleft contributing to the overall complex stability. The high target uptake and rapid non-target clearance exhibited by [(18)F]5 in PSMA(+) xenografts substantiates its potential use for PET imaging of PCa. ADVANCES IN KNOWLEDGE The only FDA-approved imaging agent for PCa, Prostascint®, targets PSMA but suffers from inherent shortcomings. The data acquired in this manuscript confirmed that our new generation of [(18)F]-labeled PSMA inhibitor exhibited promising in vivo performance as a PET imaging agent for PCa and is well-positioned for subsequent clinical trials. Implications for Patient Care Our preliminary data demonstrate that this tracer possesses the required imaging characteristics to be sensitive and specific for PCa imaging in patients at all stages of the disease.
Collapse
Affiliation(s)
| | - Shorouk Dannoon
- Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA
| | - Mark R Hopkins
- Department of Chemistry, Washington State University, USA
| | - Stephanie Murphy
- Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA
| | - Hendry Cahaya
- Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA
| | - Joseph E Blecha
- Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA
| | - Salma Jivan
- Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA
| | - Christopher R Drake
- Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA
| | | | - Ella F Jones
- Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA
| | - Henry F VanBrocklin
- Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA
| | - Clifford E Berkman
- Department of Chemistry, Washington State University, USA; Cancer Targeted Technology, USA.
| |
Collapse
|
23
|
Blecha JE, Anderson MO, Chow JM, Guevarra CC, Pender C, Penaranda C, Zavodovskaya M, Youngren JF, Berkman CE. Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs. Bioorg Med Chem Lett 2007; 17:4026-9. [PMID: 17502145 PMCID: PMC2253493 DOI: 10.1016/j.bmcl.2007.04.092] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2007] [Revised: 04/21/2007] [Accepted: 04/25/2007] [Indexed: 11/30/2022]
Abstract
Herein, we pursue the hypothesis that the structure of nordihydroguaiaretic acid (NDGA) can be refined for selective potency against the insulin-like growth factor 1 receptor (IGF-1R) as a potential therapeutic target for breast cancer while diminishing its action against other cellular targets. Thus, a set of NDGA analogs (7a-7h) was prepared and examined for inhibitory potency against IGF-1R kinase and an alternative target, 15-lipoxygenase (15 LOX). The anti-cancer effects of these compounds were determined by their ability to inhibit IGF-1 mediated cell growth of MCF-7 breast cancer cells. The design of the analogs was based upon a cursory Topliss approach in which one of NDGA's aromatic rings was modified with various substituents. Structural modification of one of the two catechol rings of NDGA was found to have little effect upon the inhibitory potency against both kinase activity of the IGF-1R and IGF-1 mediated cell growth of MCF-7 cells. 15-LOX was found to be most sensitive to structural modifications of NDGA. From the limited series of NDGA analogs examined, the compound that exhibited the greatest selectivity for IGF-1 mediated growth compared to 15-LOX inhibition was a cyclic analog 7h with a framework similar to a natural product isolated from Larrea divaricata. The results for 7h are significant because while NDGA displays biological promiscuity, 7h exhibits greater specificity toward the breast cancer target IGF-1R with that added benefit of possessing a 10-fold weaker potency against 15-LOX, an enzyme which has a purported tumor suppressing role in breast cancer. With increased specificity and potency, 7h may serve as a new lead in developing novel therapeutic agents for breast cancer.
Collapse
Affiliation(s)
- Joseph E Blecha
- Department of Chemistry & Biochemistry, San Francisco State University, San Francisco, CA 94132-4163, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Mallari JP, Choy CJ, Hu Y, Martinez AR, Hosaka M, Toriyabe Y, Maung J, Blecha JE, Pavkovic SF, Berkman CE. Stereoselective inhibition of glutamate carboxypeptidase by organophosphorus derivatives of glutamic acid. Bioorg Med Chem 2004; 12:6011-20. [PMID: 15498677 DOI: 10.1016/j.bmc.2004.08.016] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2003] [Revised: 08/06/2004] [Accepted: 08/12/2004] [Indexed: 10/26/2022]
Abstract
A series of alkyl and aryl phosphonyl, thiophosphonyl, and dithiophosphonyl derivatives of (S)- and (R)-glutamic acid were prepared and examined for inhibitory potency against glutamate carboxypeptidase (carboxypeptidase G). The acquisition of the phosphonamidodithioic acids and the individual phosphonamidothioic acid diastereomers was achieved through a common phosphonamidothiolate precursor, which also allowed for the chromatographic resolution of the chiral phosphorus center of the phosphonamidothioic acids. The most potent inhibitor of the series was the n-butylphosphonamidate derivative of the natural isomer of glutamic acid. Although each diastereomeric pair of three phosphonamidothionates exhibited stereoselective inhibition consistent with the configuration of the chiral phosphorus center, this effect was generally not remarkable. More important, was the effect of carbon stereochemistry upon glutamate carboxypeptidase inhibition as exemplified by a limited series of enantiomeric pairs of phosphonamidate and phosphonamidodithionate derivatives of glutamic acid. The phosphonamidate analogs derived from the unnatural stereoisomer of glutamic acid were devoid of inhibitory potency in contrast to their enantiomers. Surprisingly, the phosphonamidodithionates derived from the unnatural stereoisomer of glutamic acid demonstrated greater inhibitory potency than their naturally-derived antipodes.
Collapse
Affiliation(s)
- Jeremy P Mallari
- Department of Chemistry and Biochemistry, San Francisco State University, 1600 Holloway Ave., San Francisco, CA 94132, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|